medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Number 3

<< Back Next >>

Ann Hepatol 2004; 3 (3)

Effects of ribavirin on cytokine production of recall antigens and phytohemaglutinin-stimulated peripheral blood mononuclear cells. (Inhibitory effects of ribavirin on cytokine production)

Sookoian S, Castaño G, Flichman D, Cello J

Language: English
References: 20
Page: 104-107
PDF size: 52.66 Kb.


Text Extraction

Aim: To evaluate the effects of ribavirin on cytokine production of recall antigen and PHA-stimulated PBMC obtained from healthy individuals. Materials and methods: PBMC were challenged with tetanus toxoid (5µg/mL) and PHA (10 µg/mL) in absence or presence of ribavirin at different concentrations (1, 10 and 100 (µM). Parallel sets of wells containing PBMC exposed to medium alone were used as negative controls. On day 3 after initiation of the cultures, IL-2, IFN-γ, IL-4, IL-10, TNF-α content were determined in supernatants of PBMC from the different individuals. Results: The effects of ribavirin on cytokine released by human PBMC in response to PHA and TT showed a great variation among individuals. No significant changes were observed between 1-10µ M concentrations in the production of TNF-α, IFN-γ and IL-10 by both PHA and TT-stimulated PBMC. Ribavirin inhibited TNF-α, IFN-γ, and IL-10 in both PHA and TT-stimulated PBMC at 100 µM (p ‹0.05). At this concentration, ribavirin induced an increase of 124% in the production of IL-2 by PHA-stimulated PBMC (p ‹0.05). Conclusions: The present data suggest that ribavirin may cause diverse effects on immunoregulatory cytokine secretion with changes in the Th1/Th2 balance.


REFERENCES

  1. Witkowsky JT, Robins RK, Sidwell RW, Simon LN. Design, synthesis and broad spectrum activity of 1,b-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 1972; 15: 1150-54.

  2. Huffman JH, Sidwell RW, Khare GP, Witkowsky JT, Allen LB, Robins RK. In vitro effect of 1,b-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole ICN 1229) on deoxyribonucleic acid and ribonucleic viruses. Antimicrob Agents Chemother 1973; 3: 235-241.

  3. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowsky JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1,b-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 177: 705-6.

  4. Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: a new trick for an old drug? CMAJ 2003; 168(10): 1289-92.

  5. Reichard O, Yun ZB, Sönneborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 41: 99-102.

  6. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WN, Rustgin VR, Goodman ZD, Ling M-H, Cort S, Albrecht JK. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.

  7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr., Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J Med 2002; 347: 975-982.

  8. Peavy DL, Koff WC, Hymen DS, Knight V. Inhibition of lymphocyte proliferative responses by ribavirin. Infection and Immunity 1980; 29, 2: 583-89.

  9. Jolley WB, Call TW, Alvord LS, Hinshaw DB. Immunosuppressive activity of ribavirin using the rabbit skin allograft model. Ann N Y Acad Sci 1997; 284: 230-2.

  10. Marquard DL, Gruber HE, Walker LC. Ribavirin inhibits mast cell mediator release. J Pharmacol Exp Ther 1977; 240(1): 145-9.

  11. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L, Dhumeaux D. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126(3): 703-14.

  12. Klassen LW, Budman R, Williams GW, Steinberg AD, Gerber NL. Ribavirin: efficacy in the treatment of murine autoimmune disease. Science 1976; 195: 787-789.

  13. Gonzalez-Peralta RP, Davis GL, Lau YP. Pathogenic mechanism of hepatocellular damage in chronic hepatitis C. J Hepatol 1994; 21: 255-259.

  14. Parijs LV, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998; 280: 243-8.

  15. Martin J, Navas S, Quiroga JA, Pardo M, Carreño V. Effect of the ribavirin-interferon a combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998; 10, 8; 635-44.

  16. Glue P. The clinical pharmacology of Ribavirin. Semin Liver Dis 1999; 19: 17-24.

  17. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of Ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555-565.

  18. Roberts RB, Laskin OL, Laurence J, Scanuzzo D, Murray HW, Kim YT, Connor JD. Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987; 42: 365-373.

  19. Lertora JJ, Rege Ab, Lacour JT, Ferenez N, George WJ, VanDike RB, Agrawal KC, Hyslop NE. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991; 50: 442-449.

  20. Homma M, Jayewardene A, Gambertoglio J, Aweeka F. High-Performance liquid chromatographyc determination of ribavirin in whole blood to assess disposition in erythrocytes. Antimicrob Agents Chemother 1999; 43 (11): 2716-9.




2020     |     www.medigraphic.com